文献速递肝病消化道肿瘤与早癌

射频消融作为潜在可移植患者中≤3 cm肝细胞癌一线治疗的结果

Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.
PubMed 文献 · J Hepatol · 2019-01-05

这项回顾性队列研究纳入2000-2015年301例潜在可移植的新发单灶≤3 cm肝细胞癌患者,评估射频消融一线治疗后超出米兰标准的复发。HCC≤2 cm组与>2 cm组超出米兰标准复发分别为21.6%与35.1%(p=0.01),肿瘤>2 cm及甲胎蛋白100-1,000 ng/ml为预测因素;作者建议高危患者首次复发后立即考虑肝移植。

要点

  • HCC≤2 cm组超出米兰标准复发21.6%,>2 cm组35.1%(p=0.01)。
  • 肿瘤>2 cm(HR 1.94;95%CI 1.25-3.02)预测超出米兰标准复发。
  • 甲胎蛋白100-1,000 ng/ml(HR 2.05;95%CI 1.10-3.83)预测超出米兰标准复发。

核心结论

  • 射频消融治疗单发≤3 cm肝细胞癌可提供良好的短期至中期生存。
  • 研究识别出射频消融后超出米兰标准复发风险较高的患者。
  • 作者认为对这些患者应在射频消融后首次肝细胞癌复发后立即考虑肝移植。

研究设计与样本

  • 回顾性队列研究,纳入2000-2015年新诊断单灶≤3 cm肝细胞癌且接受射频消融一线治疗的潜在可移植患者。
  • 潜在可移植定义为年龄<70岁且无妨碍移植手术的合并症。
  • 共纳入301例患者,其中HCC≤2 cm组167例,HCC>2 cm组134例。
  • 按消融时肝细胞癌直径分为HCC≤2 cm组与HCC>2 cm组进行比较。
  • 采用竞争风险Cox回归识别超出米兰标准复发的预测因素。

主要发现

  • 超出米兰标准复发在HCC≤2 cm组36例(21.6%)vs HCC>2 cm组47例(35.1%)(p=0.01)。
  • 射频消融后1年、3年、5年实际生存率HCC≤2 cm组分别为98.2%、86.2%、79.0% vs HCC>2 cm组93.3%、77.6%、70.9%(p=0.01)。
  • 肿瘤大小>2 cm(风险比1.94;95%CI 1.25-3.02)为射频消融后超出米兰标准复发的预测因素。
  • 消融时甲胎蛋白100-1,000 ng/ml(风险比2.05;95%CI 1.10-3.83)为射频消融后超出米兰标准复发的预测因素。

关键数值与推荐

  • 潜在可移植患者定义:年龄<70岁且无妨碍移植手术的合并症。
  • 分组标准:消融时肝细胞癌直径HCC≤2 cm vs HCC>2 cm。
  • 预测因素阈值:肿瘤大小>2 cm;甲胎蛋白100-1,000 ng/ml。

临床怎么用

  • 作者认为对射频消融后超出米兰标准复发风险较高的患者(HCC>2 cm、甲胎蛋白100-1,000 ng/ml),应在首次肝细胞癌复发后立即考虑肝移植。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Radiofrequency ablation (RFA) is an effective treatment for single hepatocellular carcinoma (HCC) ≤3 cm. Disease recurrence is common, and in some patients will occur outside transplant criteria. We aimed to assess the incidence and risk factors for recurrence beyond Milan criteria in potentially transplantable patients treated with RFA as first-line therapy. METHODS: We performed a retrospective cohort study of potentially transplantable patients with new diagnoses of unifocal HCC ≤3 cm that underwent RFA as first-line therapy between 2000-2015. We defined potentially transplantable patients as those aged <70 years without any comorbidities that would preclude transplant surgery. Incidence of recurrence beyond Milan criteria was compared across 2 groups according to HCC diameter at the time of ablation: (HCC ≤2 cm vs. HCC >2 cm). Competing risks Cox regression was used to identify predictors of recurrence beyond Milan criteria. RESULTS: We included 301 patients (167 HCC ≤2 cm and 134 HCC >2 cm). Recurrence beyond Milan criteria occurred in 36 (21.6%) and 47 (35.1%) patients in the HCC ≤2 cm and the HCC >2 cm groups, respectively (p = 0.01). The 1-, 3- and 5-year actuarial survival rates after RFA were 98.2%, 86.2% and 79.0% in the HCC ≤2 cm group vs. 93.3%, 77.6% and 70.9% in the HCC >2 cm group (p = 0.01). Tumor size >2 cm (hazard ratio 1.94; 95%CI 1.25-3.02) and alpha-fetoprotein levels at the time of ablation (100-1,000 ng/ml: hazard ratio 2.05; 95%CI 1.10-3.83) were found to be predictors of post-RFA recurrence outside Milan criteria. CONCLUSION: RFA for single HCC ≤3 cm provides excellent short- to medium-term survival. However, we identified patients at higher risk of recurrence beyond Milan criteria. For these patients, liver transplantation should be considered immediately after the first HCC recurrence following RFA. LAY SUMMARY: Radiofrequency ablation and liver transplantation are treatment options for early stages of hepatocellular carcinoma (HCC). After ablation some patients will experience recurrence or metastatic spread of the initial tumor or may develop new tumors within the liver. Despite close follow-up, these recurrences can progress rapidly and exceed transplant criteria, preventing the patient from receiving a transplant. We identified that patients with HCC >2 cm and higher serum alpha-fetoprotein are at greater risk of recurrence beyond the transplant criteria. These data suggest that liver transplantation should be considered immediately after the first HCC recurrence for these patients.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Doyle A, Gorgen A, Muaddi H, et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol. 2019. PMID: 30615906. doi:10.1016/j.jhep.2018.12.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。